FME25 presentation

FME25

CONFERENCE CALL NOVEMBER 2, 2021

Rice Powell - CEO & Chairman Helen Giza - CFO & CTO

© C opyright

Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy or might not even be anticipated. The Company has based these forward-looking statements on current estimates and assumptions which we believe are reasonable and which are made to the best of our knowledge. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) Annual Report on Form

20-F under the heading "Forward-Looking Statements" and under the headings in that report

referred to therein, and in FMC AG & Co. KGaA's other reports filed with the Securities and Exchange Commission (SEC) and the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse).

Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the termnet income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in Euro if not mentioned otherwise.

Implementation of measures as presented herein may be subject to information & consultation procedures with works councils and other employee representative bodies, as per local laws and practice. Consultation procedures may lead to changes on proposed measures.

© C opyright

1

2

AGENDA

MID-TERM STRATEGY

FME25

FME25| EXECUTION ON STRATEGY 2025

RENAL CARE CONTINUUM

Dialysis Business, Value-Based Care models, expansion along the renal patient journey in CKD and transplant to further enhance patient experience

Expand Service and Product portfolio and establish digital care models

COMPLEMENTARY ASSETS

Leverage competencies and build new capabilities for the future of medical care models

New patient-focused therapy offerings in renal care and beyond

SUSTAINABILITY

Continuous improvements

Embedded in strategy execution

CORE - DIALYSIS PRODUCTS AND SERVICES

Dialysis Services, Dialysis Products

Leverage expertise in Services, MedTech and Pharma to maximize impact of vertical integration

CRITICAL CARE

Leverage expertise to address critical acute health challenges

Build on Extracorporeal physiological multi- organ support

FME25 Communication

11/2021

Page 4

FME25| EXECUTION ON STRATEGY 2025

STRATEGY 2025

CREATING THE FUTURE

OF HEALTH CARE FOR

CHRONICALLY AND CRITICALLY

ILL PATIENTS ACROSS THE RENAL CARE CONTINUUM BY LEVERAGING OUR CORE COMPETENCIES.

OUR CORE

COMPETENCIES

COORDINATING PATIENTS

EFFICIENTLY

STANDARDIZING MEDICAL

PROCEDURES

OPERATING OUTPATIENT

FACILITIES

INNOVATING PRODUCTS

DRIVING GROWTH & VALUE

• Creating value for patients, payors and FME while keeping care affordable by expansion of leading value-based care business in dialysis and into new patient groups along their renal disease journey
• Transforming the future of renal care with innovation - new digital tools and medical science enabling therapeutic and product innovations for holistic renal patient care
• Focused innovation and expansion of critical care portfolio to enhance growth in our MedTech business
• Enhance value by investing in new operating model

FME25 Communication

11/2021

Page 5